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Abstract
Multi-drug resistance (MDR), an unfavorable factor compromising treatment efficacy of anticancer drugs, involves
upregulated ATP binding cassette (ABC) transporters and activated Sonic hedgehog (Shh) signaling. By preparing human
breast cancer MCF-7 cells resistant to doxorubicin (DOX), we examined the effect and mechanism of norcantharidin (NCTD),
a small-molecule synthetic compound, on reversing multidrug resistance. The DOX-prepared MCF-7R cells also possessed
resistance to vinorelbine, characteristic of MDR. At suboptimal concentration, NCTD significantly inhibited the viability of
DOX-sensitive (MCF-7S) and DOX-resistant (MCF-7R) cells and reversed the resistance to DOX and vinorelbine. NCTD
increased the intracellular accumulation of DOX in MCF-7R cells and suppressed the upregulated the mdr-1 mRNA, P-gp and
BCRP protein expression, but not the MRP-1. The role of P-gp was strengthened by partial reversal of the DOX and
vinorelbine resistance by cyclosporine A. NCTD treatment suppressed the upregulation of Shh expression and nuclear
translocation of Gli-1, a hallmark of Shh signaling activation in the resistant clone. Furthermore, the Shh ligand upregulated
the expression of P-gp and attenuated the growth inhibitory effect of NCTD. The knockdown of mdr-1 mRNA had not
altered the expression of Shh and Smoothened in both MCF-7S and MCF-7R cells. This indicates that the role of Shh
signaling in MDR might be upstream to mdr-1/P-gp, and similar effect was shown in breast cancer MDA-MB-231 and BT-474
cells. This study demonstrated that NCTD may overcome multidrug resistance through inhibiting Shh signaling and
expression of its downstream mdr-1/P-gp expression in human breast cancer cells.
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Introduction
Breast cancer is a common malignant tumor in woman.
Surgical excision, chemotherapy, irradiation, and hormone
therapy are the major therapeutic options. Recently, targeted
therapy, such as Trastuzumab and lapatinib to specifically inhibit
the activity of receptors HER2/neu and epidermal-derived growth
factor receptor (EGFR1), respectively, has already become
clinically established as an effective and less toxic strategy for the
treatment of breast cancer [1,2]. However, more and more
research is indicating that tumor cell resistance to chemothera-
peutic drugs signals failure for the cancer treatment [3].
Multidrug resistance (MDR) is an unfavorable factor causing
the failure of treatments against cancer cells [4]. It occurs when
cancer cells acquire simultaneous resistance to various kinds of
chemotherapeutic agents with no structural or functional similar-
ities [5]. One of the mechanisms involved in MDR that reduces
intracellular drug accumulation is the active efflux of chemother-
apeutic agents through membrane drug transporters, especially the
ATP-binding cassette (ABC) proteins, including p-glycoprotein (P-
gp, MDR1, ABCB1), the multidrug resistance protein 1 (MRP1),
and the breast cancer resistance protein (BCRP, ABCG2) [6].
Sonic hedgehog (Shh) is a secretory signaling protein involving
embryogenesis that was first discovered in Drosophila [7]. Upon
binding the Shh ligand to its transmembranous receptor PTCH1,
the PTCH1-mediated inactivation of Smoothened (Smo) is
reversed to activate the Shh signaling pathway, resulting in
translocation of the cytoplasmic transcription factors Gli family
into the nucleus to modulate the expression of target genes
controlling the cell cycle, cell adhesion, signal transduction,
vascularization, and apoptosis [8]. We previously showed that
Sonic hedgehog (Shh) signaling pathway activation is associated
with resistance to chemoradiation in esophageal adenocarcinoma
[9] and resistance to multiple structurally unrelated chemother-
apeutic agents through regulating MDR1 and BCRP expression
[10]. This link of MDR and Shh signaling may provide a novel
target for the development of anticancer drugs reversing MDR.
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nuclear FOXC2 and Gli-1 has a significant correlation in estrogen
receptor (ER)-negative breast cancers, resulting in a poor rate of
disease-free survival [11]. By mutation analysis of 36 novel
candidate cancer genes in 96 human breast cancers, demonstrat-
ing that potential impact on protein function in the genes related
to Notch, Hedgehog, NF-kB, and PIK3CA pathways [12].
However, there was no research mentioned about the correlation
between Shh and MDR in breast cancers. Thus, clarification for
correlation between Shh signaling and MDR is crucial for
developing a new possible strategy for optimizing clinical
treatment of breast cancers.
Norcantharidin (NCTD) is a small-molecule synthetic demeth-
ylated analog of the naturally occurring cantharidin isolated from
blister beetles (Mylabris phalerata Pall.). The anticancer effects of
NCTD have been investigated and reported against a diversity of
malignancies by inducing cell anoikis and apoptosis [13],
inhibiting invasion and angiogenesis [14], and suppressing
metastasis [15]. Unlike the conventional chemotherapeutics,
NCTD is preferentially toxic to cancer cells rather than normal
cells [16], making this small molecule promising in cancer
treatment. Further, our preliminary work indicates that NCTD
may possess pharmacological activity for reversing drug resistance
in cancer cells.
To clarify the effect of NCTD on drug resistance in breast
cancer, we developed doxorubicin (DOX)-sensitive and DOX-
resistant MCF-7 cells [17]. The possible mechanisms of action,
including cell viability, drug efflux, MDR molecule expression,
Shh signaling regulation, the correlation between MDR and Shh,
and the above effects in the other breast cancer cell lines, were also
investigated.
Materials and Methods
Materials and cells
The NCTD (exo-7-oxabicylo-[2.2.1] heptane-2,3-dicarboxylic
anhydride) with analytical grade purity, doxorubicin (DOX),
cyclosporine A (CsA), and the chemicals used in this study were
purchased from Sigma (St. Louis, MO). Vinorelbine (VNR) and
Sonic Hedgehog N-terminal peptide were purchased from
GlaxoSmithKline (Middlesex, UK) and R&D systems (Minneap-
olis, MN), respectively. Human breast adenocarcinoma MCF-7
cells (estrogen receptor (ER)-positive, progesterone receptor (PR)-
positive, and HER2-low), sensitive to the chemotherapeutic drug
DOX (denoted as MCF-7S), were purchased from the American
Type Culture Collection (Manassas, VA) and were cultured in
alpha minimum essential medium (a-MEM, Invitrogen, Carlsbad,
CA) supplemented with 10% heat-inactivated fetal bovine serum
(FBS), 1.5 g/L NaHCO3, and 2 mM L-glutamine. MCF-7R cells
were developed as DOX-resistant according to the method
reported by Mechetner et al [17]. In brief, in vitro culture of
MCF-7 cells was grown in the same medium containing DOX
with the initial concentration of 10 nM. The survival cells with
drug resistant effect were selected by passaging cells in increasing
DOX concentrations till 150 nM. Cultures were maintained in a
humidified atmosphere with 5% CO2 at 37uC. The cultured cells
were subcultured twice each week, seeding at a density of about
2610
5 cells/mL. Additionally, human breast cancer cell lines BT-
474 (HER2
+ ER
+ PR
+) and MDA-MB-231 (HER2
2 ER
2 PR
2)
cells, kindly provided from Dr. Huang WC (Mackay Memorial
Hospital, Taipei, Taiwan), were cultured in Dulbecco’s modified
Eagle’s medium (Invitrogen, Carlsbad, CA) supplemented with
10% FBS, 1.5 g/L NaHCO3, and 2 mM L-glutamine.
Viability of breast cancer cells
MCF-7S and MCF-7R cells were cultured and treated with
DOX (0–300 nM), NCTD (0–50 mM), VNR (0.5 nM), Shh
peptide (0.1 mg/mL), and/or CsA (4 mM) for 48 h. Cells were
then collected and the cell viability (%) was determined by using
the 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide
(MTT, Sigma) colorimetric assay and the trypan blue dye
exclusion method. BT-474 and MDA-MB-231 cells were treated
with DOX (150 nM), NCTD (10 mM), and Shh peptide (0.1 mg/
mL) for 48 h and then assayed the viability by trypan blue dye
exclusion method.
DOX efflux
MCF-7S and MCF-7R cells with DOX (150 nM) and/or
NCTD (10 mM) treatment were harvested for 48 h. DOX could
emit red fluorescence under the excitation wave-length at 510–
550 nm. For assessment of DOX accumulation, the cells were
Table 1. Primer sequences used for the RT-PCR assay.
Genes Sequences Annealing temp.
a Products (bp)
mdr-1: 53 312
Forward 59-AAAGCTGTCAAGGAAGCCAA-39
Reverse 59-TGACTCCATCATCGAAACCA-39
Shh: 33.8 477
Forward 59-CGCACGGGGACAGCTCGGAAGT-39
Reverse 59-CTGCGCGGCCCTCGTAGTGC-39
Smo: 50.7 322
Forward 59-TTACCTTCAGCTGCCACTTCTACG-39
Reverse 59-GCCTTGGCAATCATCTTGCTCTTC-39
GAPDH: 55 574
Forward 59-CCACCCATGGCAAATTCCATGGCT-39
Reverse 59-TCTAGACGGCAGGTCAGGTCCACC-39
aThe PCR thermal cycle profile consisted of 1 cycle of denaturation for 5 min at 95uC; 35 cycles of denaturation for 30 sec at 95uC, annealing of primers for 45 sec at
different temperatures as shown in this Table, and extension for 1 min at 72uC; and 1 cycle of a final extension step at 72uC for 10 min.
doi:10.1371/journal.pone.0037006.t001
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phenotype of the cells was observed under a fluorescence
microscope at a magnification of 4006 for measuring the
percentage of cells with intracellular DOX accumulation (%).
RNA extraction and reverse transcription (RT)-PCR assay
of mdr-1, Shh, and Smo expression
The total RNA was extracted from the cells using TRIzol
reagent (Invitrogen) in accordance with the manufacturer’s
instructions. The RNA was reverse-transcribed with Superscript
II Transcriptase (Invitrogen) in the presence of oligo-dT and
random primers. For the polymerase chain reaction (PCR) assay,
the primer sequences and PCR condition for the MDR-1, Shh,
Smo, and glyceraldehyde-3-phosphate dehydrogenase (GAPDH)
genes are shown in Table 1. After PCR, the products were
analyzed on 1% agarose gels stained with ethidium bromide
(0.01%). Relative band intensities were determined using ImageJ
software (Version 1.36b, National Institute of Health, Bethesda,
Maryland). Expression levels of the GAPDH gene were used for
standardization. Each experiment was repeated at least three
times.
Western blot analysis of P-gp, MRP1, BCRP, and Shh
expression
The protein was extracted from the cells with lysis buffer (8 M
urea and 4% 3-[(3-cholamidopropyl)dimethylammonio]-1-propa-
nesulfonate detergent, Sigma) at 4uC. Then, the supernatants
containing total protein were separated by centrifugation at
10,000 g for 30 min. Protein samples (50 mg) were mixed with 26
concentrated electrophoresis sample buffer (1 M Tris, pH 6.8, 5%
SDS, 40% glycerol, 0.005% bromophenol blue, and 8% b-
mercaptoethanol), separated on a 10% SDS-polyacrylamide gel,
and transferred to polyvinylidene fluoride (PVDF) membranes.
After blocking, the blots were respectively incubated with primary
antibody directed against P-gp (1:200; Santa Cruz Biotechnology,
Heidelberg, Germany), MRP-1 (1:200; Santa Cruz), BCRP
(1:1000; Santa Cruz), Shh (1:500; Santa Cruz), or GAPDH
(1:1000, Santa Cruz) overnight at 4uC. The results were detected
using horseradish peroxidase (HRP)-conjugated anti-mouse IgG
(1:10,000 for 1 h at room temperature) followed by enhanced
chemiluminescence using ECL reagents and analyzed using a
chemiluminescence imaging system (Perkin Elmer, Waltham,
Massachusetts). The protein bands were then analyzed using the
Figure 1. Viability of the MCF-7R and MCF-7S cells. Cells were treated with (A) DOX (0–300 nM), (B) NCTD (0–50 mM), (C) a combination of
DOX (150 nM) and/or NCTD (10 mM), and (D) a combination of VNR (0.5 nM), Shh peptide (0.1 mg/mL) and/or NCTD (10 mM). After 48 h, the cell
viability was assayed by the MTT method. The results were expressed as the mean 6 SD of at least three independent experiments. *Significant
difference compared with the untreated control group.
doi:10.1371/journal.pone.0037006.g001
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GAPDH control and were calculated from at least three
independent experiments.
Immunofluorescence staining of Gli-1 distribution
The treated cells were collected and reacted with anti-Gli-1
primary antibody (1:1000, Santa Cruz) and immunofluorescence
PE-conjugated anti-IgG-TR antibody (1:500, Santa Cruz) in order
to determine the distribution of Gli-1 expression in cells. Hoechst
33342 fluorescence dye was also used to stain the location of the
nucleus. The cells were then photographed under a fluorescence
microscope at a magnification of 4006.
Correlation between P-gp and Shh signaling by mdr-1
siRNA assay
To assess the role of P-gp on Shh signaling regulation, we used
mdr-1 siRNA (HSS182278) and negative control siRNA (Invitro-
gen). In brief, the cells were transfected with 20 mM of siRNA
using lipofectamine
TM RNAiMAX reagent (Invitrogen). After
48 h, the cells were collected and the mRNA levels of mdr-1, Shh,
and Smo were analyzed by reverse transcription polymerase chain
reaction (RT-PCR) assay. Relative band intensities were deter-
mined using ImageJ software. The mean values were normalized
to the internal GAPDH control and were calculated from at least
three independent experiments.
Data analysis
Results were expressed as the mean 6 standard error (SE) from
at least three experiments. Statistical comparisons were performed
using Student’s t-test or analysis of variance as appropriate.
Differences were considered significant at a P of less than 0.05. All
statistical analyses were carried out using GraphPad Prism 4 (San
Diego, CA, USA) and SigmaPlot software (Version 9.0, Systat
Software Inc., San Jose, CA).
Results
Effect of NCTD on breast cancer MCF-7 cells possessing
MDR
In a pair of MCF-7 cell subclones, with doxorubicin-sensitive
(MCF-7S) and doxorubicin-resistant (MCF-7R) characteristics
established previously (Figure 1A) by MTT colorimetric assay,
NCTD inhibited the viability of both cell lines in a concentration-
dependent manner (Figure 1B). At suboptimal concentration
(10 mM), NCTD markedly promoted the growth inhibitory effect
of DOX (Figure 1C). The DOX-prepared resistant cells were also
resistant to vinorelbine (VNR), indicating acquirement of MDR
(Figure 1D). We found that NCTD was effective at enhancing the
growth inhibition of VNR against MCF-7R cells (Figure 1D).
Given that resistance to agents with no structural or mechanistic
similarities may be mediated by modulating the drug efflux
transporters, we next examined the effect of the known drug pump
modulator Shh ligand on drug activity. Intriguingly, Shh N-
terminal peptide subverted the growth inhibitory activity of VNR
and partially blocked the enhancing effect of NCTD (Figure 1D).
Moreover, cell viability measured by the Trypan blue dye
exclusion method had a similar result as when tested by the
MTT method (data not shown).
Figure 2. Effect of NCTD on the distribution of DOX in cells. (A) MCF-7S and (B) MCF-7R cells were treated with DOX (150 nM) and/or NCTD
(10 mM) for 48 h. Then, the cells were washed by PBS, observed under a fluorescence microscope (4006), and (C) The percentage of cells with
intracellular DOX accumulation was measured. *Significant difference between DOX alone and DOX+NCTD in the same cell type.
doi:10.1371/journal.pone.0037006.g002
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expression of drug efflux transport proteins
By using the fluorescent property of DOX, we noted that the
intracellular accumulation of DOX was significantly reduced in
the MCF-7R cells as compared to the MCF-7S cells (Figure 2).
The reduction of DOX accumulation was reversed by the NCTD
treatment in the MCF-7R cells (Figure 2B and 2C). This data
supported the effect of NCTD on drug efflux transport proteins.
To further elucidate the involved proteins, we assessed their
expression at the mRNA and protein levels. As demonstrated in
Figure 3A and 3B, both the expression of mdr-1 mRNA and its
transcribed P-gp protein were upregulated in the MCF-7R cells.
This upregulation was markedly inhibited by the NCTD
treatment. Moreover, the expression of the other ABC proteins
(BRCP, but not MRP-1) had a similar alteration profile as P-gp
(Figures 3C and 3D). CsA, a pharmacological inhibitor of P-gp
function, partially reversed the DOX and VNR but not the
NCTD resistance in the MCF-7R cells (Figure 3E), supporting the
role of P-gp in this MDR model and indicating the pump sparing
effect on NCTD.
Effect of NCTD on Shh signaling and link of P-gp
expression
As shown in Figure 4A, the expression of Shh was upregulated
in the MCF-7R cells as compared to the MCF-7S clone. By the
NCTD treatment, the Shh expression was greatly suppressed in
both cell lines (Figure 4A). The nuclear translocation of Gli-1, a
hallmark of Shh signaling activation, exhibited a similar pattern by
NCTD treatment (Figure 4B). The exogenous addition of the Shh
ligand increased the basal expression of Shh and P-gp in the MCF-
7S cells (Figure 4C), suggesting a possible regulatory role of Shh
upstream P-gp. This increase in MCF-7R cells was not evident,
which may be due to high basal expression. The addition of the
Shh ligand, validated by the enhanced expression of Shh
(Figure 4C), moderately reduced the growth inhibitory effect of
NCTD in both the MCF-7S and MCF-7R cells (Figure 4D). To
further exclude the possibility that P-gp acts upstream of Shh, we
knocked down the mdr-1 gene and found no significant changes in
the expression of Shh and Smo in both the MCF-7S and MCF-7R
cells (Figure 5). Taken together, establishment of multidrug
resistance in the MCF-7 cells may result in the upregulation of
Figure 3. Expression of mdr-1/P-gp, BCRP, and MPR-1 in MCF-7S and MCF-7R cells. (A) RT-PCR assay of mdr-1 mRNA level in DOX and/or
NCTD-treated cells. Western blotting of (B) P-gp, (C) BCRP, and (D) MPR-1 expression in DOX and/or NCTD-treated cells. (E) Viability of DOX, VNR, and
NCTD in MCF-7R cells with or without CsA (4 mM) treatment. Cells were cultured with a DOX (150 nM) and/or NCTD (10 mM) treatment for 48 h. Then,
the cells were washed by PBS and their total RNA and proteins for RT-PCT and Western blot analysis, respectively, were extracted. To clarify the role of
MDR-related gene and protein expression, MCF-7R cells were treated with or without CsA, and then assayed for cell viability. GAPDH was used as the
internal control. The relative expression of each band was assayed and the data were expressed as the mean 6 SD of at least three independent
experiments. *Significant difference as compared to the untreated control.
#Significant difference between MCF-7S and MCF-7R (B–D) and the CsA
treatment and non-treatment (E) at the same treatment of NCTD.
doi:10.1371/journal.pone.0037006.g003
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treatment could reverse the multidrug resistance through suppres-
sion of these unfavorable molecular events.
Effect in other breast cancer cells
As shown in Figure 6A, cell viability were increased with Shh
peptide treatment in MDA-MB-231and BT-474 cells. NCTD
inhibited the cell growth and had synergistic effect with DOX to
eliminate the cell viability that increased by Shh peptide. In
Figure 6B, the expression of N-Shh and P-gp were also
upregulated in Shh-treated MDA-MB-231and BT-474 cells, while
treatment of NCTD and NCTD plus DOX effectively decreased
the levels of N-Shh and P-gp. Moreover, BT-474 cells, HER2/
neu, ER and PR-triple positive cells, were less sensitive to NCTD
plus DOX-mediated cytotoxity and expressed higher P-gp level
when the cells treated with Shh peptide.
Discussion
The unique characteristics of NCTD include small-molecule,
simple synthesis procedures [18], a leukocytosis effect instead of
Figure 4. Effect of Shh signaling in cells with and without DOX and/or NCTD treatment. (A) Expression of N-Shh by Western blot assay. (B)
Gli-1 translocation by immunofluorescence assay. (C) Western blot analysis of N-Shh and P-gp expression in cells with and without Shh peptide and/
or NCTD treatment. (D) Cell viability assay of cells with and without Shh peptide and/or NCTD treatment. MCF-7S and MCF-7R cells were cultured
with DOX (150 nM) and/or NCTD (10 mM) treatment for 48 h. Then, the cells were washed by PBS and their total proteins extracted for Western blot
analysis. For the Gli-1 translocation assay, the cells were stained with Hoechst33342 and fluorescence-conjugate anti-Gli-1 antibody, and then
observed under a fluorescence microscope. To clarify the role of Shh on multidrug resistance, the Shh peptide and/or NCTD were treated in the cells,
and the N-Shh and P-gp expression and cell viability were assayed by Western blotting and the MTT method, respectively. GAPDH was used as the
internal control and the results were confirmed by at least three independent experiments. *Significant difference as compared to the untreated
control.
#Significant difference between MCF-7S and MCF-7R (A) and the Shh peptide treatment and non-treatment (D) at the same treatment of
DOX and/or NCTD.
doi:10.1371/journal.pone.0037006.g004
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evidence shows NCTD may have pharmaceutical potential to be
developed as a novel category of anticancer drugs. NCTD is
known as a potent anticancer drug against various types of cancer
cells [13,16]. In our previous study, we demonstrated that NCTD
inhibited pulmonary metastasis of colorectal cancer CT26 cells in
vivo and cell invasion ability in vitro, accompanied by the
downregulation of MMP-9 [20]. Furthermore, NCTD downreg-
ulated MMP-9 promoter activity through the inhibition of Sp-1
transactivation in colorectal cancer cells [15]. In clinical practice,
cancer cells’ resistance to chemotherapeutic drugs usually limits
the efficacy of treatment outcome. On the basis of direct
cytotoxicity, we further extended the study to investigate the
effect of NCTD on multidrug resistance in cancer cells.
There are two general categories related to drug resistance:
acquired and intrinsic. Both the intrinsic and acquired resistance
of human tumors to chemotherapy is a multifactorial event, often
leading to a lack of response to several unrelated drugs (multidrug
resistance or MDR). Intrinsic resistance reflects the inability of a
drug to target a particular organism, such as outer membrane
impermeability and efflux pumps. Decreased intracellular drug
accumulation due to reduced permeability of the plasma
membrane, found in the MOS/IR1 cells, is one possible
mechanism and may explain the intrinsic resistance to multidrug
chemotherapy for the treatment of osteosarcoma [21]. While
acquired resistance is the result of mutational resistance arising
from gene mutation, transmissible resistance, multidrug resistance
(MDR), etc [21]. Mechanisms involved in MDR include overex-
pression of multispecific ATP-dependent drug efflux pumps, such
as P-gp (MDR1, ABCB1), MRP1, and BCRP (ABCG2), that
reduce the concentration of the drug available for cancer cells [6].
In HepG2 cells, an article reported that cantharidin reversed
multidrug resistance via downregulation of P-gp expression [22].
This study demonstrated that NCTD increased the intracellular
accumulation of DOX in the MCF-7R cells and suppressed the
upregulated mdr-1 mRNA, P-gp and BCRP protein expressions,
but not the MRP-1. Moreover, it concludes that NCTD may
overcome multidrug resistance via a novel drug resistance
pathway, sonic hedgehog (Shh) signaling.
The Shh signaling pathway has been proven to be related to
resistance to chemotherapy and chemoradiation in cancer cells
[23]. We found that the chemotherapy resistance in MCF-7 breast
cancer cells was independent of the mechanism of drugs,
indicating a correlation to drug efflux activity. This generous
multidrug resistance may compromise the clinical efficacy of
chemotherapeutics against cancer cells. We further demonstrated
that Shh might be the upstream modulator for this generous
resistance machinery, indicating that Shh signaling could be a
drug development target for a broad and salvage inhibitor of drug-
resistance clones in breast cancer. Additionally, HER2/neu, ER,
PR, and EGFR are highly expressed in many cases of breast
cancers and considered important biomarkers [24,25]. HER2
overexpression causes high rate of cell proliferation and lymph
node involvement, which is correlated with disease aggressiveness,
increased rates of recurrence and poorer survival in breast cancer
patients [25]. This study demonstrated that Shh-mediated tumor
growth was universal in various cell lines of breast cancer,
including MCF-7 (HER2
2 ER
+ PR
+), MCF-7R, MDA-MB-231
(HER2
2 ER
2 PR
2), and BT-474 (HER2
+ ER
+ PR
+) cells. It
implicates that NCTD may benefit the therapeutic efficacy against
various types of breast cancer cells via inhibiting Shh signaling and
MDR. In clinical practice, the survival of triple negative breast
cancer patients remains unsatisfactory. An article reported that
10% to 20% of breast cancer patients express no or low levels of
ER, PR and HER2, showing poor response to chemotherapeutic
agents [26]. The major reason for the poorer prognosis might has
been regarded no actual targets for therapeutics. Our results
indicated that NCTD was effective against cell ontogeny with
triple negative. Collectively, it implicates that the clinical outcome
and shortage of effective treatment might be overcome by Shh
inhibitors, such as NCTD and the other small molecule
therapeutics according to results of this study.
Currently investigations into inhibitors for Shh signaling include
Smo or Gli-1 blockers. Among these inhibitors, the Smo
antagonist vismodegib (GDC-0449) has been proven effective in
phase I/II clinical trials against basal cell carcinoma [27] and
medulloblastoma [28]. However, a D473H mutation in Smo has
been reported causing resistance to GDC-0449 in medulloblasto-
ma [29]. Therefore, the development of various Shh signaling
inhibitors to overcome resistance or as a salvage therapy should be
a critical task in treating the refractory cancers. Our result
indicates NCTD may be a potential candidate for both a primary
and a salvage therapeutic agent against Shh-activating cancer
cells.
Shh signaling has been demonstrated involving cancer angio-
genesis, metastasis, invasion [30]. For example, Shh signaling
could promote the metastasis of gastric cancer cells through
activation of the PI3K/Akt pathway, which may lead to epithelial
mesenchymal transition and MMP-9 activation [31]. NCTD has
been reported to have bioactivity against these cancer cell
pathways. Whether NCTD has direct chemical interaction with
Shh signaling molecules, like arsenic trioxide and Gli-1 [32], or
indirect regulation of the signaling pathway remains to be
examined.
Collectively, this study demonstrated that NCTD was effective
at inhibiting the growth of both DOX-sensitive (MCF-7S) and
DOX-resistant (MCF-7R) breast cancer cell lines and reversed the
cells’ resistance to chemotherapeutic drugs, including DOX and
vinorelbine. The upstream Shh signaling pathway was blocked in
NCTD-treated MCF-7S and MCF-7R cells, and then the
expression of MDR molecules was downregulated, especially
mdr-1/P-gp. Moreover, the other breast cancer cell lines,
including MDA-MB-231 (HER2
2 ER
2 PR
2) and BT-474
(HER2
+ ER
+ PR
+), also have the similar effects. In conclusion,
our results suggest that the small-molecule compound NCTD may
Figure 5. Expression of mdr-1, Shh, and Smo in cells with and
without mdr-1 siRNA treatment. To clarify the role of P-gp on the
regulation of Shh signaling molecules, mdr-1 siRNA was used to knock
down the P-gp expression in both the MCF-7S and MCF-7R cell lines.
Expression of mdr-1, Shh, and Smo mRNA levels was analyzed by RT-
PCR assay. GAPDH was used as the internal control and the results were
confirmed by at least three independent experiments. *Significant
difference as compared to the untreated control.
doi:10.1371/journal.pone.0037006.g005
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and its downstream mdr-1/P-gp expression in human breast
cancer cells.
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Figure 6. Effect of Shh signaling in human breast cancer MDA-MB-231 and BT-474 cells. (A) Cell viability assay. (B) Expression of N-Shh
and P-gp by Western blotting. Cells were cultured with or without Shh peptide (0.1 mg/mL), NCTD (10 mM) or NCTD plus DOX (150 nM) treatment for
48 h. The treated cells were collected, assayed the viability by using trypan blue dye exclusion test, and then their total proteins were extracted for
Western blot analysis. Expression of N-Shh and P-gp levels were normalized to GAPDH and the results were confirmed by at least three independent
experiments. *Significant difference as compared to the untreated control.
#Significant difference as compared to the Shh alone group.
doi:10.1371/journal.pone.0037006.g006
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